Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0YFXJU
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Anti-FGFR2 mAb-10846 SPDB-DM4
|
|||||
| Synonyms |
Anti-FGFR2-mAb-10846-SPDB-DM4
Click to Show/Hide
|
|||||
| Organization |
Novartis AG
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 3 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Investigative
Colorectal cancer [ICD11:2B91]
Investigative
Gastric cancer [ICD11:2B72]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
3-4
|
|||||
| Antibody Name |
Anti-FGFR2 mAb 10846
|
Antibody Info | ||||
| Antigen Name |
Fibroblast growth factor receptor 2 (FGFR2)
|
Antigen Info | ||||
| Payload Name |
Mertansine DM4
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)
|
Linker Info | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.